Kristof Cuppens

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

D. Ross Camidge, Jair Bar, Hidehito Horinouchi et al. · Journal of Clinical Oncology · 2024 · 99 citations · Full text

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Jair Bar, Nir Peled, Shiruyeh Schokrpur et al. · Journal of Thoracic Oncology · 2022 · 92 citations · Full text

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Byoung Chul Cho, Jong Seok Lee, Yi‐Long Wu et al. · Journal of Thoracic Oncology · 2023 · 71 citations · Full text

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Martin Schüler, Kristof Cuppens, Till Plönes et al. · Nature Medicine · 2024 · 70 citations · Full text

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors

Kristof Cuppens, Paul Baas, Ellen Geerdens et al. · Lung Cancer · 2022 · 23 citations · Full text